North Dakota · 86769

Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody in North Dakota

North Dakota Medicare Avg
$41.29
0% above national avg
National Medicare Avg
$41.21
All states combined
Billed Charge (ND)
$121.47
What providers submit
Est. Commercial (ND)
$82.58
National avg: $92.31
Est. Cash / Self-Pay (ND)
$64.37
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

14
Services in ND
2
Providers
N/A
Min Payment
N/A
Max Payment

North Dakota Pricing in Context

In North Dakota, CPT code 86769 (Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody) carries an average Medicare payment of $41.29 — 0% above the national benchmark of $41.21. 2 providers across the state submitted claims for this procedure in 2023, performing 14 total services. Individual payments in ND ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in North Dakota is $121.47, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because North Dakota sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Immunology procedures, the estimated commercial insurance price in North Dakota lands near $82.58, with self-pay cash prices typically around $64.37. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody cost in North Dakota?

The average Medicare payment for Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody in North Dakota is $41.29, which is 0% above the national average of $41.21. Providers in ND typically bill $121.47 for this procedure.

What does Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody cost with insurance in North Dakota?

With commercial insurance in North Dakota, Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody costs an estimated $82.58. Without insurance, the estimated cash price is $64.37. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody in North Dakota?

2 providers in North Dakota billed Medicare for Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody in 2023, performing 14 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody cheaper in North Dakota than the national average?

No — Measure Of Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) Antibody costs 0% above the national average in North Dakota. The state average Medicare payment is $41.29 compared to $41.21 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial